Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 6 Lymphoma, B-Cell 3 Lymphoma 3 Leukemia, Lymphocytic, Chronic, B-Cell 2 Lymphoma, Non-Hodgkin 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Hodgkin Disease 1 Burkitt Lymphoma 1

Interventions

Rituximab 25 Lenalidomide 21 Cyclophosphamide 20 Prednisone 14 obinutuzumab 12 Vincristine 12 Doxorubicin 11 Magnetic Resonance Spectroscopy 10 Bendamustine Hydrochloride 9 Specimen Handling 8 ibrutinib 7 Biopsy 7 fludarabine 6 pembrolizumab 5 fludarabine phosphate 5 Radiotherapy 5 Peripheral Blood Stem Cell Transplantation 5 zanubrutinib 4 venetoclax 4 tazemetostat 4 Whole-Body Irradiation 4 R-CHOP protocol 4 Prednisolone 3 Mycophenolic Acid 3 Etoposide 3 Cyclosporine 3 tisagenlecleucel 2 polatuzumab vedotin 2 orelabrutinib 2 loncastuximab tesirine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Follicular × tafasitamab × 90 days × Clear all

NCT07585747 2026-05-14

CUREMZL002

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Not yet recruiting

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡